STAT3 and interstitial lung disease: In this study 7 out of 21 (i.e., 33%) patients, all pediatric ones, achieved complete remission of STAT3-GOF-associated manifestations, whereas the rest displayed disease activity, more commonly in the form of lymphoproliferation or ILD, despite treatment with a JAKi.